FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant fusion proteins containing a mutant of domain of human SIRPα, and can be used in medicine in the treatment of tumors. The following is constructed: a fusion protein that contains a first binding domain that specifically binds to PD-L1 linked directly or indirectly through a linker to a second binding domain that specifically binds to CD47 protein. The second binding domain contains a mutant of domain of human SIRPα.
EFFECT: invention makes it possible to obtain a fusion protein capable of simultaneously specifically binding to CD47 protein and PD-L1, and specifically blocking the interaction between CD47 protein and SIRPα, as well as between PD-1 and PD-L1 and effectively inhibit the growth and/or proliferation of tumors or tumor cells.
35 cl, 10 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
